PharmNovo is a clinical-stage biotechnology company developing PN6047, a drug candidate that is advancing toward a Phase II study. The company recently completed a financing round of roughly 39 million kronor to fund that planned Phase II trial. KDventures AB, which holds PharmNovo in its portfolio, announced the capital raise and concurrently wrote down the book value of its holding to 5 million kronor. The financing included participation from external investors, though specific investor names beyond KDventures were not disclosed. No revenue, user metrics, or prior funding round details were provided in the articles.

Total raised

$27M

Funding rounds

5

Latest round

Equity

Latest activity

Jul 2026